PD-L1 is a positive predictive biomarker of ICIs, which has been prospectively validated and approved by the Food and Drug Administration, and was also positively associated with outcomes for ICIs in EGFR mutant NSCLC.[4]. Here, EGFR is linked to non-small cell lung carcinoma.